First patient enrolled in the project’s clinical study
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile
Presentation of INTERCEPT-T2D’s Coordinator in the FFD newsletter (in french)
*Article in French* Read an article made by our partner “the Federation Française des diabétiques” about the project’s coordinator Nicolas Venteclef and the project INTERCEPT-T2D in their newsletter
2nd consortium meeting 6&7 December Basel
The consortium met again in Basel on the 6&7 of December to review the progress and accomplishments of the year 2023.
Horizon Europe – a Swiss Success Story with Prof. Dr. Marc Donath from University Hospital Basel
Listen to Dr. Marc Donath, Head of Clinic for Endocrinology, Diabetes & Metabolism, Uni Spital Basel speaking about INTERCEPT-T2D
INTERCEPT-T2D present at the annual congress of the French Diabetic Society
The coordinator and its lab were present at the annual meeting of the diabetic society..
INTERCEPT-T2D kick-off
The project kick-off has taken place on the 11th and 12th of January in Paris at Necker Institute.
TUD’s announcement of the project
Please find a communication from our project partner